Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Piramal Life Sciences Head Sees First Drug Launch In Two-Three Years

This article was originally published in PharmAsia News

Executive Summary

CEO Ajay Piramal of Piramal Life Sciences, a recent spinoff of Piramal Healthcare, says the move enables the firm to become the first in India to launch globally its own discovered molecule. He said such a move would be a first because the "culture of research" has not existed in India. He said in an interview Piramal Life has six molecules in clinical trials, all in collaboration with global pharmaceuticals such as Eli Lilly, Merck and Pierre Fabre. The firm expects its first drug to reach the market as early as early as 2010. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel